Cannabiz Issue 1
The publication provides a 360 degree spotlight about the Medical Cannabiz industry, specifically in Malta, covering topics related to regulatory issues, operators, affiliates and SEO trends, new mergers and acquisitions.
The publication provides a 360 degree spotlight about the Medical Cannabiz industry, specifically in Malta, covering topics related to regulatory issues, operators, affiliates and SEO trends, new mergers and acquisitions.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
COVER STORY<br />
CAN YOU BRIEFLY DESCRIBE WHAT<br />
ALVIT DOES?<br />
At its core, Alvit researches and develops<br />
pharma-grade cannabis products,<br />
helping cannabis communicate in a<br />
language doctors understand. We are<br />
currently constructing a very impressive<br />
EU-GMP certified cannabis cultivation,<br />
extraction and production facility in the<br />
EU in Malta and will be launching our<br />
flowers, oils and pharma-grade products<br />
into Europe in the beginning of 2020.<br />
WITH BUSINESSES JOSTLING FOR<br />
SPACE IN THE NASCENT CANNABIS<br />
INDUSTRY, WHAT IS ALVIT DOING<br />
THAT DISTINGUISHES IT FROM OTHER<br />
COMPANIES IN THE INDUSTRY?<br />
WHAT MAKES IT THE FUTURE?<br />
In order to elaborate on what<br />
distinguishes us, I need to provide you<br />
with a drop of background information.<br />
Our company was founded by Nachshol<br />
Cohen. Nachshol has been involved<br />
with the medical cannabis markets<br />
long before their inception, both in<br />
Israel and internationally. In Israel,<br />
he is recognised as one of the true<br />
visionaries in the field. He has always<br />
been a trendsetter and his name has<br />
become known globally throughout the<br />
cannabis industry.<br />
So when medical cannabis started<br />
being legalised in more and more<br />
jurisdictions around the world, and a<br />
mad rush to secure cultivation licenses<br />
in the US, Canada, and other locations<br />
ensued, Nachshol recognised that the<br />
future of medical cannabis did not end<br />
with flowers and oils, and that the true<br />
market growth for the industry would<br />
come from pharma-grade products that<br />
doctors recognise, understand, and are<br />
accustomed to prescribing.<br />
So while the rest of the market was<br />
trying to learn how to grow flowers,<br />
Nachshol signed on Yoram Sela, the<br />
founder of Teva Pharmaceuticals<br />
drug delivery unit, who went on to run<br />
it for 9 years. Six years later we’ve<br />
already created a full line of pharmagrade<br />
cannabis products that we will<br />
be producing in 2020 in our EU-GMP<br />
certified facility in Malta. So I guess<br />
that’s what distinguishes us. We’re<br />
the ‘future’ and we’re also the ‘now’<br />
because we started six years early with<br />
a clear vision. We have what doctors<br />
want to prescribe.<br />
CAN YOU DESCRIBE THE FACILITY<br />
YOU’RE CONSTRUCTING IN MALTA?<br />
WHAT WILL IT BE ABLE TO PRODUCE?<br />
We’re constructing a massive seed-topharma<br />
facility that will be the heart of<br />
our European operation going forward.<br />
We will have our own nursery under<br />
“We’re constructing a massive seed-to-pharma facility that<br />
will be the heart of our European operation going forward”<br />
CANNABIZ .1<br />
30
Change language